Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.
Sirima SB, Tiono AB, Ouédraogo A, Diarra A, Ouédraogo AL, Yaro JB, Ouédraogo E, Gansané A, Bougouma EC, Konaté AT, Kaboré Y, Traoré A, Chilengi R, Soulama I, Luty AJ, Druilhe P, Cousens S, Nébié I. Sirima SB, et al. Among authors: cousens s. PLoS One. 2009 Oct 26;4(10):e7549. doi: 10.1371/journal.pone.0007549. PLoS One. 2009. PMID: 19855847 Free PMC article. Clinical Trial.
Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria?
Nebie I, Tiono AB, Diallo DA, Samandoulougou S, Diarra A, Konate AT, Cuzin-Ouattara N, Theisen M, Corradin G, Cousens S, Ouattara AS, Ilboudo-Sanogo E, Sirima BS. Nebie I, et al. Among authors: cousens s. Trop Med Int Health. 2008 Feb;13(2):229-37. doi: 10.1111/j.1365-3156.2007.01994.x. Trop Med Int Health. 2008. PMID: 18304269 Free article.
Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa.
Sirima SB, Nébié I, Ouédraogo A, Tiono AB, Konaté AT, Gansané A, Dermé AI, Diarra A, Ouédraogo A, Soulama I, Cuzzin-Ouattara N, Cousens S, Leroy O. Sirima SB, et al. Among authors: cousens s. Vaccine. 2007 Mar 30;25(14):2723-32. doi: 10.1016/j.vaccine.2006.05.090. Epub 2006 Jun 16. Vaccine. 2007. PMID: 17280744 Clinical Trial.
Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial.
Konaté AT, Yaro JB, Ouédraogo AZ, Diarra A, Gansané A, Soulama I, Kangoyé DT, Kaboré Y, Ouédraogo E, Ouédraogo A, Tiono AB, Ouédraogo IN, Chandramohan D, Cousens S, Milligan PJ, Sirima SB, Greenwood B, Diallo DA. Konaté AT, et al. Among authors: cousens s. PLoS Med. 2011 Feb 1;8(2):e1000408. doi: 10.1371/journal.pmed.1000408. PLoS Med. 2011. PMID: 21304925 Free PMC article. Clinical Trial.
Morbidity from malaria in children in the year after they had received intermittent preventive treatment of malaria: a randomised trial.
Konaté AT, Yaro JB, Ouédraogo AZ, Diarra A, Gansané A, Soulama I, Kangoyé DT, Kaboré Y, Ouédraogo E, Ouédraogo A, Tiono AB, Ouédraogo IN, Chandramohan D, Cousens S, Milligan PJ, Sirima SB, Greenwood BM, Diallo DA. Konaté AT, et al. Among authors: cousens s. PLoS One. 2011;6(8):e23391. doi: 10.1371/journal.pone.0023391. Epub 2011 Aug 12. PLoS One. 2011. PMID: 21858097 Free PMC article. Clinical Trial.
Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children.
Bougouma EC, Palacpac NMQ, Tiono AB, Nebie I, Ouédraogo A, Houard S, Yagi M, Coulibaly SA, Diarra A, Tougan T, Ouedraogo AZ, Soulama I, Arisue N, Yaro JB, D'Alessio F, Leroy O, Cousens S, Horii T, Sirima SB. Bougouma EC, et al. Among authors: cousens s. Front Immunol. 2022 Aug 31;13:978591. doi: 10.3389/fimmu.2022.978591. eCollection 2022. Front Immunol. 2022. PMID: 36119062 Free PMC article. Clinical Trial.
399 results